Chief Investment Officer, Sarissa Capital Management LP

Alex Denner, Ph.D., has been investing in healthcare companies for the past two decades. In 2013, he founded Sarissa Capital Management to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector.

Dr. Denner has led Sarissa’s involvement in some of biopharma’s most successful strategic transactions and activist campaigns, including the sales of Idenix to Merck and ARIAD to Takeda and the spinoff from Biogen and subsequent sale of Bioverativ to Sanofi.

Prior to founding Sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital. At Icahn, he developed Icahn’s activist strategy in healthcare and was responsible for some of the firm’s most successful investments, including ImClone, Genzyme, Amylin, MedImmune, Biogen and Forest Laboratories. Prior to joining Icahn, he was a healthcare portfolio manager at Morgan Stanley Investment Management and at Viking Global.

Dr. Denner currently serves as a director of Biogen and as Chairman of The Medicines Company. He previously served as Chairman of ARIAD and director of Amylin Pharmaceuticals, Bioverativ and ImClone. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.